Tryptophan dendrimers that inhibit HIV replication, prevent virus entry and bind to the HIV envelope glycoproteins gp120 and gp41. 2015

Eva Rivero-Buceta, and Elisa G Doyagüez, and Ignacio Colomer, and Ernesto Quesada, and Leen Mathys, and Sam Noppen, and Sandra Liekens, and María-José Camarasa, and María-Jesús Pérez-Pérez, and Jan Balzarini, and Ana San-Félix
Instituto de Química Médica (IQM-CSIC), Juan de la Cierva 3, 28006 Madrid, Spain.

Dendrimers containing from 9 to 18 tryptophan residues at the peryphery have been efficiently synthesized and tested against HIV replication. These compounds inhibit an early step of the replicative cycle of HIV, presumably virus entry into its target cell. Our data suggest that HIV inhibition can be achieved by the preferred interaction of the compounds herein described with glycoproteins gp120 and gp41 of the HIV envelope preventing interaction between HIV and the (co)receptors present on the host cells. The results obtained so far indicate that 9 tryptophan residues on the periphery are sufficient for efficient gp120/gp41 binding and anti-HIV activity.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014364 Tryptophan An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals. Ardeydorm,Ardeytropin,L-Tryptophan,L-Tryptophan-ratiopharm,Levotryptophan,Lyphan,Naturruhe,Optimax,PMS-Tryptophan,Trofan,Tryptacin,Tryptan,Tryptophan Metabolism Alterations,ratio-Tryptophan,L Tryptophan,L Tryptophan ratiopharm,PMS Tryptophan,ratio Tryptophan
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications

Related Publications

Eva Rivero-Buceta, and Elisa G Doyagüez, and Ignacio Colomer, and Ernesto Quesada, and Leen Mathys, and Sam Noppen, and Sandra Liekens, and María-José Camarasa, and María-Jesús Pérez-Pérez, and Jan Balzarini, and Ana San-Félix
January 2003, Current pharmaceutical design,
Eva Rivero-Buceta, and Elisa G Doyagüez, and Ignacio Colomer, and Ernesto Quesada, and Leen Mathys, and Sam Noppen, and Sandra Liekens, and María-José Camarasa, and María-Jesús Pérez-Pérez, and Jan Balzarini, and Ana San-Félix
September 2006, Proceedings of the National Academy of Sciences of the United States of America,
Eva Rivero-Buceta, and Elisa G Doyagüez, and Ignacio Colomer, and Ernesto Quesada, and Leen Mathys, and Sam Noppen, and Sandra Liekens, and María-José Camarasa, and María-Jesús Pérez-Pérez, and Jan Balzarini, and Ana San-Félix
January 1997, Microbiology and immunology,
Eva Rivero-Buceta, and Elisa G Doyagüez, and Ignacio Colomer, and Ernesto Quesada, and Leen Mathys, and Sam Noppen, and Sandra Liekens, and María-José Camarasa, and María-Jesús Pérez-Pérez, and Jan Balzarini, and Ana San-Félix
March 2004, Retrovirology,
Eva Rivero-Buceta, and Elisa G Doyagüez, and Ignacio Colomer, and Ernesto Quesada, and Leen Mathys, and Sam Noppen, and Sandra Liekens, and María-José Camarasa, and María-Jesús Pérez-Pérez, and Jan Balzarini, and Ana San-Félix
August 2004, Preparative biochemistry & biotechnology,
Eva Rivero-Buceta, and Elisa G Doyagüez, and Ignacio Colomer, and Ernesto Quesada, and Leen Mathys, and Sam Noppen, and Sandra Liekens, and María-José Camarasa, and María-Jesús Pérez-Pérez, and Jan Balzarini, and Ana San-Félix
January 1995, AIDS (London, England),
Eva Rivero-Buceta, and Elisa G Doyagüez, and Ignacio Colomer, and Ernesto Quesada, and Leen Mathys, and Sam Noppen, and Sandra Liekens, and María-José Camarasa, and María-Jesús Pérez-Pérez, and Jan Balzarini, and Ana San-Félix
February 2008, Journal of molecular biology,
Eva Rivero-Buceta, and Elisa G Doyagüez, and Ignacio Colomer, and Ernesto Quesada, and Leen Mathys, and Sam Noppen, and Sandra Liekens, and María-José Camarasa, and María-Jesús Pérez-Pérez, and Jan Balzarini, and Ana San-Félix
July 2021, Vaccines,
Eva Rivero-Buceta, and Elisa G Doyagüez, and Ignacio Colomer, and Ernesto Quesada, and Leen Mathys, and Sam Noppen, and Sandra Liekens, and María-José Camarasa, and María-Jesús Pérez-Pérez, and Jan Balzarini, and Ana San-Félix
January 2022, Advances in experimental medicine and biology,
Eva Rivero-Buceta, and Elisa G Doyagüez, and Ignacio Colomer, and Ernesto Quesada, and Leen Mathys, and Sam Noppen, and Sandra Liekens, and María-José Camarasa, and María-Jesús Pérez-Pérez, and Jan Balzarini, and Ana San-Félix
January 2000, Microbiology and immunology,
Copied contents to your clipboard!